Intelligence Feed event · Macro · 2026-09-24

    Vertex Reports Positive Phase IIb Kidney Disease Data for Inaxaplin

    Question

    Vertex Reports Positive Phase IIb Kidney Disease Data for Inaxaplin

    Direct answer

    Vertex Pharmaceuticals disclosed results from its Phase IIb AMPLIFIED trial evaluating inaxaplin. The candidate generated a 42.7% reduction in UACR among AMKD patients with modest baseline proteinuria, alongside a 17.3% drop in patients presenting concurrent type II diabetes. With enrollment in the registration-enabling Phase II/III AMPLITUDE trial fully complete, the data supports pipeline diversification beyond the core CF franchise into multi-billion-dollar rare kidney disease markets.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-24
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Vertex Reports Positive Phase IIb Kidney Disease Data for Inaxaplin”, revision 1, evidence through 2026-09-24. https://marketontology.com/market-events/2026-09-24/vertex-reports-positive-phase-iib-kidney-disease-data-for-inaxaplin-b50280

    MACRO
    Vertex Reports Positive Phase IIb Kidney Disease Data for Inaxaplin
    Vertex Pharmaceuticals disclosed results from its Phase IIb AMPLIFIED trial evaluating inaxaplin. The candidate generated a 42.7% reduction in UACR among AMKD patients with modest baseline proteinuria, alongside a 17.3% drop in patients presenting concurrent type II diabetes. With enrollment in the registration-enabling Phase II/III AMPLITUDE trial fully complete, the data supports pipeline diversification beyond the core CF franchise into multi-billion-dollar rare kidney disease markets.
    VRTX
    Impact
    72
    SEP 24
    SIG
    85%
    VRTX
    Vertex Reports Positive Phase IIb Kidney Disease Data for Inaxaplin
    Vertex Pharmaceuticals disclosed results from its Phase IIb AMPLIFIED trial evaluating inaxaplin. The candidate generated a 42.7% reduction in UACR among AMKD patients with modest baseline proteinuria, alongside a 17.3% drop in patients presenting concurrent type II diabetes. With enrollment in the registration-enabling Phase II/III AMPLITUDE trial fully complete, the data supports pipeline diversification beyond the core CF franchise into multi-billion-dollar rare kidney disease markets.
    → Statistically significant proteinuria reductions expand VRTX addressable commercial pipeline value in non-cystic fibrosis nephrology indications.
    Impact
    Vertex Pharmaceuticals disclosed results from its Phase IIb AMPLIFIED trial evaluating inaxaplin. The candidate generated a 42.7% reduction in UACR among AMKD patients with modest baseline proteinuria, alongside a 17.3% drop in patients presenting concurrent type II diabetes. With enrollment in the registration-enabling Phase II/III AMPLITUDE trial fully complete, the data supports pipeline diversification beyond the core CF franchise into multi-billion-dollar rare kidney disease markets.
    Affected
    VRTX
    Transmission
    Statistically significant proteinuria reductions expand VRTX addressable commercial pipeline value in non-cystic fibrosis nephrology indications.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    VRTXpipeline net present value repricing on positive late-stage efficacyUp1-4wAMPLIFIED study showed 42.7% UACR reduction with pivotal trial enrollment complete

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    VRTXUpdisagreed522.38 2026-09-24+0.73%-2.99%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month